Business context and reporting period
The filing is Cyclacel Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2017—not a filing for Bio Green Med Solution, Inc., as indicated in the request metadata. Cyclacel is a clinical-stage biopharmaceutical company developing cancer therapies. Its principal programs include CYC065, a CDK inhibitor in a Phase 1 trial; sapacitabine with seliciclib in a Phase 1 combination study; and analysis of the Phase 3 SEAMLESS AML study.
Financial results and liquidity
Amounts below are in U.S. dollars; financial statement amounts are presented in thousands unless stated otherwise.
| Metric | Q3 2017 | Q3 2016 | Nine months 2017 | Nine months 2016 |
|---|---|---|---|---|
| Grant revenue | $0 | $205,000 | $0 | $566,000 |
| Research and development expense | $958,000 | $2.409 million | $3.491 million | $7.545 million |
| General and administrative expense | $1.154 million | $1.273 million | $3.802 million | $4.002 million |
| Operating loss | $2.112 million | $3.477 million | $7.293 million | $10.981 million |
| Net loss | $1.857 million | $2.946 million | $5.599 million | $8.952 million |
| Net loss applicable to common shareholders | $8.918 million | $2.996 million | $12.761 million | $9.102 million |
| Operating cash used | Not separately stated | Not separately stated | $5.260 million | $7.136 million |
There was no product revenue in the periods shown; 2017 revenue was zero after prior-year government grant revenue ended. Profit margins are not meaningful for this pre-commercial, loss-making company. Q3 basic and diluted loss per common share was $0.91, versus $0.86 in Q3 2016; nine-month loss per share was $2.06 versus $2.89.
At September 30, 2017, cash and cash equivalents were $26.025 million, current assets $27.817 million, current liabilities $4.265 million, working capital $23.552 million, total assets $27.851 million, and total liabilities $4.393 million. No material debt balance is identified in the presented balance sheet. Management said cash was expected to fund operating and capital needs through the end of 2019, while substantial additional capital would be needed to advance programs beyond that point. Nine-month financing cash inflow was $14.600 million, primarily from equity issuance; the company used $11,000 in investing activities.
Material changes versus prior comparable periods
- Nine-month operating cash use fell by $1.876 million year over year, and net loss narrowed by $3.353 million.
- Nine-month R&D expense declined 54% to $3.491 million, mainly because spending on sapacitabine and the SEAMLESS Phase 3 trial fell as sites were closed. Q3 R&D expense fell 60% year over year.
- G&A expense was relatively flat: down 5% for the nine-month period and 9% for Q3.
- Cash increased from $16.520 million at December 31, 2016 to $26.025 million at September 30, 2017, primarily due to a July public offering and at-the-market share sales.
- Common-shareholder losses include $3.638 million for the Series A preferred stock beneficial conversion feature and $3.373 million related to its conversion in 2017. These items explain why common-shareholder loss increased despite a lower reported net loss.
- Comprehensive loss for the nine months was $5.617 million; foreign currency translation and intercompany-loan adjustments materially affected other comprehensive income.
Outlook, risks, contingencies and unusual items
- Management expected R&D spending to decrease for 2017 as SEAMLESS sites closed, and G&A spending to remain relatively flat. Any SEAMLESS regulatory submission depends on final data and regulatory discussions; the company was completing data analysis and planned to present results at an American Society of Hematology meeting.
- Management stated that available cash and expected sources would cover planned needs through 2019, but viability beyond then depends on raising further capital. Financing may not be available on acceptable terms or at all; absent funding, Cyclacel may need to reduce, delay, partner, or stop development programs.
- The July 2017 public offering generated approximately $13.7 million net proceeds and included common shares, Series A preferred shares, and warrants. At September 30, 7.59 million warrants were outstanding at a $2.00 exercise price, expiring in 2024. The offering and preferred-stock conversions created potential dilution.
- There may be up to $10.0 million of future Daiichi Sankyo milestone payments, contingent on contractual milestones, and royalties may be due on future sapacitabine sales.
- Research and development tax-credit benefits depend on eligible spending and are expected to decrease with lower R&D expenditures. Grant funding for the CYC140 program ended; future grant availability was uncertain.
- Other income for the nine months included approximately $907,000, primarily related to an asset purchase agreement with Life Technologies. The timing and amount of any future receipts are uncertain. Foreign exchange movements also affect results.
- Management reported effective disclosure controls as of September 30, 2017 and no material changes in internal control over financial reporting during the quarter. The filing reported no legal proceedings and no material changes to previously disclosed risk factors.
Most important facts an investor should verify
- Confirm the issuer: the supplied filing identifies Cyclacel Pharmaceuticals, Inc., not Bio Green Med Solution, Inc.
- Review the final SEAMLESS Phase 3 data and any subsequent regulatory advice, submissions, or decisions.
- Assess whether the stated cash runway through 2019 remains achievable and what financing is required afterward.
- Evaluate dilution from the July offering, preferred-stock conversions, and outstanding warrants.
- Check clinical progress and funding needs for CYC065 and the sapacitabine/seliciclib study, along with contingent licensing obligations.